PRESS RELEASES
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024: Nature Biotechnology, a transformative journal covering the science and business of biotechnology, published a review article on the significant challenges facing molecular glue companies seeking to remove undruggable disease-causing proteins, highlighting the innovative differentiated approach advanced by SEED Therapeutics among a few other companies. In a section titled “Sticking without glue” the author of the Nature Biotechnology review article Ken Garber discussed the strategy pioneered by SEED founders Lan Huang, PhD, Ning Zheng, PhD, Michele Pagano MD, and Avram Hershko MD, PhD, of selecting the right E3 ligase from the >600 available in the human genome to increase the probability of success in the extensive drug development efforts that follow the E3 ligases selection decision. James Tonra, PhD, the President and CSO of SEED Therapeutics was furthermore quoted in the article to emphasize two key components of the RITE3 platform for molecular glue discovery at SEED:
- The E3 ligase binds to the target protein without a molecular glue to be selected
- The E3 ligase associates to some extent with the target protein in cells
As Ken Garber notes, “It won’t be easy” to develop Molecular Glues, but the current investment of time and money into molecular glue discovery at small and large pharmaceutical companies indicates the potential importance to patients recognized in industry and academia. SEED Therapeutics is proud to be highlighted as a leader in developing potentially transformative solutions to realize the potential of this approach to treat numerous currently intractable diseases.
For details of this publication, please contact IR@SEEDTherapeutics.com
LATEST PRESS RELEASES
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025 Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models;...
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago Two PROTAC synergy using two E3 ligases for achieving levels of degradation of...
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors King of Prussia, PA – January 28,...
Nature: Protein degraders push into novel target space
info@seedtherapeutics.com info@seedtherapeutics.com PUBLICATIONS Nature: Protein degraders push into novel target space Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head...
SEED Therapeutics Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of...
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a...
SEED Theraputics, a BeyondSpring Subsiniary, Appoints Mr. Ko-Yung Tung to the Board of Directors
info@seedtherapeutics.com info@seedtherapeutics.com PRESS RELEASES SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law...
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
info@seedtherapeutics.cominfo@seedtherapeutics.com PRESS RELEASES Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors New York, NY – June 20, 2023 – SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary...
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania
info@seedtherapeutics.cominfo@seedtherapeutics.com PRESS RELEASESSeed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania. King of Prussia, PA – July 01, 2022 –...